Synthetic Genomics, Inc.
11149 North Torrey Pines Road
About Synthetic Genomics, Inc.
42 articles with Synthetic Genomics, Inc.
Synthetic Genomics, Inc., a leader in designing and programming biology for function, today announced J. Craig Venter, Ph.D., has retired from his longtime position as Chairman of the company’s Board of Directors to focus on his work at the J. Craig Venter Institute. Dr. Venter will remain a Scientific Advisor to SGI.
Life Sciences Industry Veteran Todd R. Nelson Named SGI-DNA CEO to Lead Spin-out from Synthetic Genomics
SGI-DNA announced industry veteran Todd R. Nelson, Ph.D., MBA has been appointed Chief Executive Officer to lead the spin-out of the company from Synthetic Genomics, Inc. (SGI).
Synthetic Genomics Appoints Reinhard J. Ambros, Ph.D., Former Global Head of the Novartis Venture Fund to Board of Directors
Dr. Ambros was the global head of the Novartis Venture Fund from 2005 to 2017 and built one of the largest and most active corporate Biotechnology Venture Funds globally.
Oliver Fetzer, Ph.D., MBA, Chief Executive Officer, will present at the upcoming Bank of America Merrill Lynch 2018 Healthcare Conference and the Jefferies 2018 Global Healthcare Conference.
C3J Therapeutics Bolsters Antimicrobial R&D Program; Acquires Engineered Bacteriophage Assets from Synthetic Genomics
C3J Therapeutics and Synthetic Genomics, Inc., (SGI) a leader in designing and programming biology for desired function, announced an agreement between the two companies to integrate SGI’s proprietary engineered bacteriophage (or phage) platform with C3J’s R&D programs addressing high unmet medical needs linked to infectious diseases.
Synthetic Genomics and Ceva Enter Agreement to Develop, Commercialize Next-Generation Vaccines for Animal Health
Synthetic Genomics announced today that the company has entered into a collaboration with Ceva Sante Animale to utilize Synthetic Genomics' next-generation synthetic RNA replicon platform to develop vaccines for livestock.
Arcturus Therapeutics and Synthetic Genomics Announce Strategic Alliance to Develop Next-Generation Vaccines and Therapeutics
The collaboration will bring together Arcturus's LUNAR lipid-mediated delivery platform with Synthetic Genomics' RNA replicon platform to potentially enable more efficacious and lower cost vaccines and therapeutics.
Synthetic Genomics, Inc. Launches cGMP Suite For Pharmaceutical Quality Manufacturing Of Synthetic DNA For Advaxis' Clinical Trials
Digital-To-Biological Converter For On-Demand Production Of Biologics Developed By Synthetic Genomics, Inc.
Synthetic Genomics, Inc. Launches Vmax Express, A Next-Generation Protein Expression Platform For The Biotech Industry
Synthetic Genomics, Inc. Announces Collaboration With Johnson & Johnson Innovation To Develop Novel Therapeutics Using Synthetic Genomics' Replicon RNA Technology
Synthetic Genomics, Inc. Team Engineers Vmax, An Advantaged Next-Generation Host Organism For A Wide Range Of Biotechnology Applications
Teams At Venter Institute And Synthetic Genomics, Inc. Successfully Engineer 16S rRNA Using One Step Process Combining CRISPR/Cas9 Systems And Yeast Recombination Machinery
SGI-DNA, A Synthetic Genomics, Inc. Company, Announces Exclusive Global Distribution Agreement For Reagents With VWR
First Minimal Synthetic Bacterial Cell Designed And Constructed By Scientists At Venter Institute And Synthetic Genomics, Inc.